(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
25 March 2010 (25.03.2010)

PCT

(10) International Publication Number
WO 2010/033426 A3

(51) International Patent Classification:
A61K 31/195 (2006.01) *A61K 38/00* (2006.01)
A61K 31/20 (2006.01) *A61K 38/40* (2006.01)
A61K 31/7088 (2006.01) *A61P 35/00* (2006.01)
A61K 35/74 (2006.01) *A61P 37/04* (2006.01)

(21) International Application Number:
PCT/US2009/056599

(22) International Filing Date:
11 September 2009 (11.09.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/098,258 19 September 2008 (19.09.2008) US
61/241,074 10 September 2009 (10.09.2009) US

(71) Applicants *(for all designated States except US)*: **NESTEC S.A.** [CH/CH]; Avenue Nestle 55, CH-1800 Vevey (CH). **INSTITUT CURIE** [FR/FR]; 26 Rue d'Ulm, F-75248 Paris Cedex 05 (FR).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **SCHIFFRIN, Eduardo** [CH/CH]; Chemin de Riant-Mont 17, CH-1023 Crissier (CH). **MILLER, Kevin Burke** [US/US]; 2200 Milwaukee Avenue, Minneapolis, Minnesota 55404 (US). **BRASSART, Dominique** [FR/CH]; Rte de la Plaine 5, CH-1022 Chavannes-Pres-Renes (CH). **LANTZ, Olivier Jacques** [FR/FR]; 133 Avenue Felix Faure, F-75015 Paris (FR). **AMIGORENA, Sebastian Diego** [FR/FR]; 32 rue des Cordelieres, F-75013 Paris (FR).

(74) Agent: **LOBEL, Gary M.**; Nestlé Healthcare Nutrition, 12 Vreeland Road, 2nd Floor, P.O. Box 697, Florham Park, New Jersey 07932 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:
18 November 2010

(54) Title: NUTRITIONAL SUPPORT TO PREVENT AND/OR MITIGATE BONE MARROW TOXICITY FROM A CANCEROUS TUMOR

(57) Abstract: The present invention relates to methods and immunonutritional compositions for preventing or mitigating paralysis of the bone marrow, caused by a tumor or neoplasm, between cycles of and after anti-cancer therapy, thereby attaining a better efficacy of the treatment. More particularly, the present invention relates to methods and immunonutritional compositions that can transiently preventing or moderating, bone marrow paralysis or neutropenia of a subject tumor-induced apoptosis or necrosis or other cell damage such that the innate and adaptive immune functions and normal physiology of the bone marrow are preserved, at least in part, which, in turn, lead to (i) a better tolerance and increased efficacy to treatment; (ii) transient augmentation or enhancement of immunocompetence of the immune cell; and (iii) optimization of the effects of and increase of immunocompetence of the immune cell weakened due to paralysis of the bone marrow, caused by a tumor or neoplasm.

WO 2010/033426 A3